Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
about
Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancerPrognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patientsGALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.Is there a role for intensive therapy in breast cancer?Is Higher Efficacy Always at the Price of More Side Effects during Chemotherapy?The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy.Association between treatment toxicity and outcomes in oncology clinical trialsNeutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study.Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancersLeucopenia and treatment efficacy in advanced nasopharyngeal carcinoma.Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma.Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMFModerate neutropenia with adjuvant CMF confers improved survival in early breast cancer.Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer.Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03.Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia.Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy.Effects of hypogonadism on bone metabolism in female adolescents and young adults.Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review.Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.Chemotherapy-induced myelotoxicity and incidence of lung metastasis in an animal model.Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer.Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy.Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer.Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.Are medical oncologists biased in their treatment of the large woman with breast cancer?Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer.Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia.Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels.Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
P2860
Q33402694-1791D425-AB20-4597-8B82-E7A989530F62Q33413622-BA120FC3-5228-45C3-9D1F-66EA0C1922FDQ33733830-84D407D5-14D8-450F-ADD1-A656DBCC25DCQ33804685-B528FB8F-E812-4074-9784-EB19F624DEC6Q34095821-6BD93040-C7EB-4BE5-AB3B-4B1E8C9FAB1AQ34277890-0E9FC149-0170-4D52-AC4D-5DACBAE5AEE4Q34395352-51CEEF31-743F-48DA-8F5D-26D8BA8B1B9CQ35171432-BEE27C25-9C0F-4CFD-96D7-DCCDC572973BQ35212672-4E4479F1-6D7F-4976-9680-7DC192DA3A1AQ35602282-2899FD61-1659-4555-BA9C-4F5AD3BF7183Q35640038-AD97E0FB-7CF4-4FFE-AF5F-8B0EFA1EEB37Q36379148-89ABB3CA-867C-4316-9963-55DA1F74D45AQ36608664-BF17C844-7CBE-4B0C-B123-71E550A0E748Q36610747-80E33F9D-8BA4-411A-AC70-A288DDA13C0FQ36620540-42E665D8-38D1-4EDB-B1DE-1AD941E77201Q36671677-085D80CA-8895-4F4A-91EF-08A63FF7E32AQ37034836-8BB2C93C-F9CC-4EE4-B5DD-89C44297517AQ37424017-9FD76018-56BE-465F-AA2F-1CD94B455A93Q37652706-5A307DD7-71DA-4AE6-B7E9-B4D488D40710Q37801578-BC63BD83-EFEF-4064-9416-78CBA08BAFA5Q37978208-4C31F194-4370-47BC-A87A-BA0F32DF69F3Q38037349-207DEEF9-02F1-47C4-9558-B78AD7A1A0B1Q38705873-2297ED75-3F78-465E-B077-F35D259AD5D2Q39680258-D3CB32D2-7B29-4439-9D07-79CAB5492826Q39955429-A95908E8-B0D9-4BD0-B599-53DC51687CC0Q40306765-1E0C86BD-7E1A-48C2-A250-B16EC93BCD62Q40330557-1340A054-2D09-48B4-90CC-255C2937BEAAQ41565292-A4BB642A-06F5-4E42-B676-12F094E189A4Q42380313-2111EF2B-8D1B-4FD3-BC9C-3C4365BA6C2FQ43524982-EAD9DF52-92C2-431A-B597-C55A6E999214Q43631694-DBEE0ED4-3105-4669-AEB3-4285CA6B72C6Q43661609-729F555F-2503-47CD-8821-BC963B6BFD3BQ44477565-B359DA58-230A-4ED5-BF3B-855DC2B5C11AQ45848898-04D55CC8-FAA3-4B2E-9DE8-78C489AC81B5Q45850052-A6DCFEB4-CB6B-4DAC-AACA-3E2D62DF272FQ47391721-8D1029CB-FAA4-4FBF-BE9D-09A2799BB429Q52599791-016D9989-C0E2-4F7D-8581-22E6FFA0C61AQ53050079-C7C62779-C75D-47D8-8A1B-3B7B31433F0CQ53195496-AAB09CCF-B543-42B7-A2F5-B607C60F8BECQ54561366-0B36B0D3-BA3C-492A-8F80-F3CDCBD029B1
P2860
Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Haematological toxicity: a mar ...... stage II and III breast cancer
@ast
Haematological toxicity: a mar ...... stage II and III breast cancer
@en
type
label
Haematological toxicity: a mar ...... stage II and III breast cancer
@ast
Haematological toxicity: a mar ...... stage II and III breast cancer
@en
prefLabel
Haematological toxicity: a mar ...... stage II and III breast cancer
@ast
Haematological toxicity: a mar ...... stage II and III breast cancer
@en
P2093
P2860
P356
P1476
Haematological toxicity: a mar ...... stage II and III breast cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1997.49
P407
P577
1997-01-01T00:00:00Z